カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の神経バイオマーカー市場（2023-2030）：用途別（アルツハイマー病、パーキンソン病、多発性硬化症、自閉症）、種類別、エンドユーザー別、地域別

【英語タイトル】Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism), By Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV175）・商品コード：GRV23NOV175
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：120
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：臨床診断
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

神経バイオマーカー市場の成長と動向
Grand View Research社の最新レポートによると、世界の神経バイオマーカー市場は20230年までに187億5000万米ドルに達する見込みです。同市場は、2023年から2030年にかけて年平均成長率12.8%で成長する見込みです。新薬開発を後押しする神経バイオマーカーの研究開発に対する資金提供の増加が市場成長を後押しする見込みです。米国国立神経疾患・脳卒中研究所（National Institute of Neurological Disorders and Stroke）は、臨床的検証、分析的検証、バイオマーカー探索に関連する研究を行う研究者に、共同研究契約や開発助成金などの資金提供の機会を提供しています。

バイオマーカーは神経疾患治療薬の開発に重要な役割を果たします。近年、神経疾患治療薬の研究開発への投資が大幅に増加しています。例えば、2020年12月、非営利研究財団であるTarget ALSは、ALSの新規バイオマーカーの発見に焦点を当てたプロジェクトに1,500万米ドルの研究資金を提供することを発表しました。

高いS/N比を有するデジタル化されたELISA検査であるQuanterix Simoa（単一分子アレイ）のような技術的に高度な製品の利用可能性です。この技術は、神経疾患関連のバイオマーカーに関連する血液脳関門の問題を克服するのに役立ちます。このような技術の進歩は、市場の成長を促進すると期待されています。例えば、アボット社は2021年1月、脳震盪を含む外傷性脳損傷のための初の迅速血液検査を発表しました。この検査は、外傷性脳損傷後に血液中に検出される特定のタンパク質を測定するもので、検査結果が陰性の場合、CTスキャンの必要性を除外するために使用できます。

特に発展途上国や低開発国では、このような診断製品に関する認知度の欠如やその高コスト、神経科医の利用可能性の制限や不在といった要因が、このようなバイオマーカーに基づく診断ソリューションの採用に影響を与える可能性があります。世界神経学連合（World Federation of Neurology）がWHO加盟国63/84カ国を対象に行った調査によると、31/63カ国の神経科医の大多数は大都市に勤務していました。1人の神経科医が約6,240人から4,750,000人の人口にサービスを提供していました。

神経バイオマーカー市場レポートハイライト

- 2022年には、プロテオミクスタイプが最大の市場シェアを占め、予測期間中もその優位性を維持すると予測されます。

- パーキンソン病分野は、罹患率の上昇と研究開発活動の活発化により、最大の市場シェアを占めています。

- 最終用途別では、研究機関およびその他のセグメントが神経バイオマーカー市場を支配しました。神経疾患の治療薬開発のために共同研究を行っている研究機関は、薬剤耐性を評価するためにバイオマーカーを利用しています。

- 北米は、米国とカナダに強力なプレゼンスを持つ市場プレイヤーの存在と、新規バイオマーカー開発のための政府資金の増加により、市場を支配しています。

- アジア太平洋地域は、日本やオーストラリアのような先進国で技術的に高度な診断製品の採用が進んでいること、中国やインドのような発展途上国でこれらの製品の採用が増加していることから、予測期間中に大きな成長が見込まれます。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界の神経バイオマーカー市場：タイプ別予測・動向分析
第5章. 世界の神経バイオマーカー市場：用途別予測・動向分析
第6章. 世界の神経バイオマーカー市場：最終用途別予測・動向分析
第7章. 世界の神経バイオマーカー市場：地域別予測・動向分析
第8章. 競合分析

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definition
1.1.1.1 Application Segment
1.1.1.2 Type Segment
1.1.1.3 End Use Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Application and Type Snapshot
2.3 End Use Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Neurological Biomarkers Market Variables, Trends, and Scope
3.1 Neurological Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Pipeline Analysis
3.3.1 Alzheimer’s Disease
3.3.2 Parkinson’s Disease
3.3.3 Multiple Sclerosis
3.3.4 Autism Spectrum Disorder
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing Prevalence Of Neurological Diseases
3.4.1.2 Technological Advancements
3.4.1.3 Increased Funding For R&D In Biomarkers
3.4.2 Market Restraint Analysis
3.4.2.1 Lack Of Consumer Awareness
3.4.2.2 Reimbursement Policies
3.5 Neurological Biomarkers: Market Analysis Tools
3.5.1 Industry Analysis – Porter’s
3.5.2 Pestle Analysis
Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 – 2030 (USD Million)
4.1 Neurological Biomarkers Market: Type Movement Analysis
4.1.1 Genomic
4.1.1.1 Genomic Neurological Biomarkers Market, 2018 – 2030 (USD Million)
4.1.2 Proteomic
4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 – 2030 (USD Million)
4.1.3 Metabolomic
4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 – 2030 (USD Million)
4.1.4 Imaging
4.1.4.1 Imaging Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.5 Others
4.1.5.1 Others Neurological Biomarkers Market, 2018 – 2030 (USD Million)
Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 – 2030 (USD Million)
5.1 Neurological Biomarkers Market: Application Movement Analysis
5.1.1 Alzheimer’s Disease
5.1.1.1 Alzheimer’s Disease Market, 2018 – 2030 (USD Million)
5.1.2 Parkinson’s Disease
5.1.2.1 Parkinson’s Disease Market, 2018 – 2030 (USD Million)
5.1.3 Multiple Sclerosis
5.1.3.1 Multiple Sclerosis Market, 2018 – 2030 (USD Million)
5.1.4 Autism Spectrum Disorder
5.1.4.1 Autism Spectrum Disorder Market, 2018 – 2030 (USD Million)
5.1.5 Others
5.1.5.1 Others Market, 2018 – 2030 (USD Million)
Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2018 – 2030 (USD Million)
6.1 Neurological Biomarkers Market: End Use Movement Analysis
6.1.1 Hospital & Hospital Laboratories
6.1.1.1 Hospitals & Hospital Laboratories Market, 2018 – 2030 (USD Million)
6.1.2 Independent Clinical Diagnostic Centers
6.1.2.1 Independent Clinical Diagnostic Centers Market, 2018 – 2030 (USD Million)
6.1.3 Research Organizations And Others
6.1.3.1 Research Organizations and Others Market, 2018 – 2030 (USD Million)
Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 – 2030 (USD Million)
7.1 Regional Market Snapshot
7.2 North America
7.2.1 North America Neurological Biomarkers Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Regulatory Framework
7.2.2.4 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Regulatory Framework
7.2.3.4 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.2 UK
7.3.2.1 UK Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.4 Spain
7.3.4.1 Spain Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.5 France
7.3.5.1 France Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Italy Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Denmark Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Sweden Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Regulatory Framework
7.3.8.4 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Regulatory Framework
7.3.9.4 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Regulatory Framework
7.4.2.4 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.4 India
7.4.4.1 India Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.5 South Korea
7.4.5.1 South Korea Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Thailand Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.7 Australia
7.4.7.1 Australia Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Mexico Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.6 MEA
7.6.1 MEA Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Regulatory Framework
7.6.3.4 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Regulatory Framework
7.6.5.4 Reimbursement Scenario
Chapter 8 Neurological Biomarkers Market: Competitive Analysis
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New product launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.2.5 Funding
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 ABBOTT
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 JOHNSON & JOHNSON SERVICES, INC.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 BIO-RAD LABORATORIES, INC.
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 ALSERES PHARMACEUTICALS, INC.
8.4.4.1 Company overview
8.4.4.2 Product benchmarking
*Pipeline candidate
8.4.5 BANYAN BIOMARKERS, INC.
8.4.5.1 Company overview
8.4.5.2 Product benchmarking
8.4.5.3 Strategic initiatives
8.4.6 RULES-BASED MEDICINE
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic initiatives
8.4.7 THERMO FISHER SCIENTIFIC, INC.
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 DIAGENIC ASA
8.4.8.1 Company overview
8.4.8.2 Product benchmarking
8.4.9 MERCK & CO., INC.
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 QUANTERIX
8.4.10.1 Company overview
8.4.10.2 Product benchmarking
8.4.10.3 Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 11 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 12 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 13 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 14 U.K. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 15 U.K. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 16 U.K. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 17 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 18 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 19 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 20 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 21 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 22 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 23 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 24 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 25 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 26 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 27 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 28 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 29 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 30 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 31 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 32 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 33 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 34 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 35 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 36 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 37 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 38 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 39 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 40 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 41 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 42 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 43 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 44 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 45 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 46 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 47 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 48 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 49 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 50 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 51 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 52 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 53 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 54 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 55 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 56 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 57 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 58 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 59 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 60 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 61 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 62 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 63 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 64 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 65 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 66 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 67 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Neurological biomarkers market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Segment snapshot (Type and application)
Fig. 11 Segment snapshot (End-use)
Fig. 12 Competitive landscape snapshot
Fig. 13 Biomarkers market value, 2022 (USD Million)
Fig. 14 Neurological biomarkers market dynamics
Fig. 15 Prevalence of Alzheimer's disease by age group, 2021
Fig. 16 Neurological biomarkers market: PORTER’s analysis
Fig. 17 Neurological biomarkers market: PESTLE analysis
Fig. 18 Neurological biomarkers market: Type outlook and key takeaways
Fig. 19 Neurological biomarkers market: Type movement analysis
Fig. 20 Genomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Proteomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Metabolomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Imaging market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Other neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Neurological biomarkers market: Application outlook and key takeaways
Fig. 26 Neurological biomarkers market: Application movement analysis
Fig. 27 Alzheimer’s disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Parkinson’s disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Autism spectrum disorder market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Neurological biomarkers market: End-use outlook and key takeaways
Fig. 33 Neurological biomarkers market: End-use movement analysis
Fig. 34 Hospitals & hospital laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Independent clinical diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Research organizations and others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Neurological biomarkers market revenue, by region, 2022 & 2030 (USD Million)
Fig. 38 Regional marketplace: Key takeaways
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Key country dynamics
Fig. 42 U.S. neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Target disease prevalence
Fig. 44 Key country dynamics
Fig. 45 Canada neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Target disease prevalence
Fig. 47 Europe neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 UK neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Germany neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Target disease prevalence
Fig. 53 Key country dynamics
Fig. 54 France neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Italy neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Spain neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Denmark neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Sweden neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Norway neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Target disease prevalence
Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Japan neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Target disease prevalence
Fig. 71 Key country dynamics
Fig. 72 China neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 India neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Target disease prevalence
Fig. 76 Key country dynamics
Fig. 77 Australia neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Key country dynamics
Fig. 79 Thailand neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 South Korea neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Brazil neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Mexico neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 Argentina neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 South Africa neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Target disease prevalence
Fig. 95 Key country dynamics
Fig. 96 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Target disease prevalence
Fig. 98 Key country dynamics
Fig. 99 UAE neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Target disease prevalence
Fig. 101 Key country dynamics
Fig. 102 Kuwait neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Target disease prevalence
Fig. 104 Key payors in Kuwait
Fig. 105 Rest of MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Key company categorization
Fig. 107 Company market positioning
Fig. 108 Company market share analysis, 2022
Fig. 109 Strategic framework

★調査レポート[世界の神経バイオマーカー市場（2023-2030）：用途別（アルツハイマー病、パーキンソン病、多発性硬化症、自閉症）、種類別、エンドユーザー別、地域別] (コード：GRV23NOV175)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の神経バイオマーカー市場（2023-2030）：用途別（アルツハイマー病、パーキンソン病、多発性硬化症、自閉症）、種類別、エンドユーザー別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の神経バイオマーカー市場2024-2030：用途別（アルツハイマー病、パーキンソン病、多発性硬化症、自閉症）、種類別、エンドユーザー別、地域別
  • 世界の脳インプラント市場2023-2030：製品別（深部脳刺激装置、脊髄刺激装置、迷走神経刺激装置）、用途別（慢性疼痛、てんかん、パーキンソン病、うつ病、本態性振戦、アルツハイマー病）、地域別
  • 世界の神経リハビリ機器市場予測2023年-2028年：製品タイプ別（神経ロボットデバイス、ウェアラブルデバイス、非侵襲性刺激装置、ブレイン・コンピュータ・インターフェイス）、用途別（脳卒中、多発性硬化症、パーキンソン病、脳性麻痺、その他）、エンドユーザー別（病院・クリニック、認知ケアセンター、その他）、地域別
  • 世界の仮想神経リハビリテーションデバイス市場予測2023-2029：脳卒中、パーキンソン病、多発性硬化症、脊髄損傷、脳性麻痺、その他
  • 世界の脳深部刺激機器市場2023-2030：製品別（シングルチャンネル、デュアルチャンネル）、用途別（パーキンソン病、てんかん）、エンドユーザー別（病院、ASC）、地域別（アジア太平洋、北米）
  • 特殊医薬品流通のグローバル市場（2023-2030）：エイズ、血友病、多発性硬化症
  • 世界の神経刺激装置市場2023-2030：用途別（疼痛管理、パーキンソン病）、製品別（脊髄刺激装置、胃電気刺激装置）
  • 世界の網膜静脈閉塞症治療市場（2023-2030）：エンドユーザー別（小売薬局、病院・診療所）、疾患種類別（CRVO、BRVO）、治療薬別（抗VEGF薬、副腎皮質ステロイド薬）、地域別
  • 世界の尿路感染症検査市場（2023-2030）：種類別（尿道炎、膀胱炎、腎盂腎炎）、エンドユーザー別（レファレンスラボラトリー、一般開業医、泌尿器科医）、地域別
  • 世界の結石破砕装置市場（2023-2030）：種類別（体外衝撃波、体腔内衝撃波）、用途別（腎結石、膵臓結石）、エンドユーザー別（病院）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆